Tools for optimising treatment & management of advanced NETs

Prof. Emily Bergsland is a Professor of Medicine and the Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology at the University of California-San Francisco (UCSF). She has spent twenty years developing a clinical and research program focused on neuroendocrine tumours. Her clinical and research efforts are focused on advancing the care of patients with neuroendocrine neoplasms (NENs), understanding why NENs develop, and the development and testing of novel, biologically based therapies for NENs. Dr Bergsland is the Director of the University of California-San Francisco (UCSF) Centre for Neuroendocrine Tumours, Chair of the UCSF GI Oncology Site Committee and an active member of the Phase I Site Committee. Nationally, she is Chair of the Neuroendocrine Tumour Task Force of the National Cancer Institute (NCI) Gastrointestinal (GI) Steering Committee, a member of the NCCN Neuroendocrine Tumours Guidelines Panel, and is the current Vice-Chair (Chair-elect) of the North American Neuroendocrine Tumour Society (NANETS). She was also study chair for ALLIANCE A021202 (a randomized phase II trial of pazopanib v placebo in patients with progressive carcinoid tumours), a completed study which included a prospective plan for central review and archiving of serial radiologic images and blood sample collection for angiome profiling (analyses are pending).

Prof. Louis de Mestier, MD, PhD, is Full Professor of Gastroenterology at Université Paris-Cité, and serves as a Senior Consultant in the Department of Pancreatology and Digestive Oncology in Beaujon Hospital (APHP, Clichy, France). His main area of clinical expertise, research and teaching is digestive neuroendocrine neoplasms. He conducts clinical and translational research on the clinical and biological heterogeneity of neuroendocrine neoplasms and its therapeutic applications at the INSERM U1149 Research Unit in Paris. He has contributed to more than 170 medical publications, including more than 100 indexed papers in the field of neuroendocrine neoplasms. He is a member of the Advisory Boards of ENETS and GTE.